Dengue Testing Market – Industry Structure Evaluation, Demand Drivers Analysis, Regional Growth Analysis and Identification, Competitive Positioning Review & Global Market Size Forecast to 2034
Overview
Dengue Testing Market size is expected to reach nearly USD 1197.14 Mn. by 2034 with the CAGR of 5.5% during the forecast period.
Dengue Testing Market Overview:
Dengue fever is a mosquito-borne disease that affects people. ELISA or PCR-based blood tests are the most frequent methods for diagnosing the dengue virus. Rapid point-of-care assays, which have recently been developed, allow for early detection and notification of the disease.
Dengue Testing Market Snapshot
To know about the Research Methodology :- Request Free Sample Report
Dengue Testing Market Dynamics:
Rising cases of Dengue fever every year boosts the market growth.
An increase in the prevalence of dengue fever and increased awareness initiatives to teach about the afflictions of dengue are driving the growth of the worldwide dengue virus diagnostic testing market. In recent years, the number of cases of dengue fever has risen dramatically. Africa, the Americas, the Eastern Mediterranean, Southeast Asia, and the Western Pacific are the major dengue-affected regions in the world. Around 500,000 of these cases progress to dengue haemorrhagic fever or severe dengue, a more severe form of the disease that causes up to 25,000 deaths worldwide each year.
The demand for cost-efficient test kits with high specificity and sensitivity is driven by a lack of effective diagnostic tools and the high cost of existing test kits. As a result, firms in this market are currently concentrating on the development of cost-effective and reliable dengue diagnostic technologies. Climate change is projected to increase the prevalence of dengue fever, which will fuel the growth of the dengue testing market. Despite the high level of awareness of dengue prevention and treatment, there are a number of hurdles, including insufficient financing and resources, as well as a lack of a clear plan to address the growing difficulties associated with dengue epidemics in many parts of the world. Rapid urbanization, a lack of sanitation, increased international trade, and population movement stifles efforts to reduce pollution.
The report has profiled seventeen key players in the market from different regions. However, report has considered all market leaders, followers and new entrants with investors while analyzing the market and estimation the size of the same. Increasing R&D activities in each region are different and focus is given on the regional impact on the cost, availability of advanced technology are analyzed and report has come up with recommendations for future hot spot in APAC region.
Dengue Testing Market Segment Analysis:
Dengue Testing Market is segmented on the basis of Test Type and End-Users.
Based on Test Type, the ELISA-based segment is expected to account for dominant market share during the forecast period. An enzyme-linked immunosorbent test (ELISA), which analyses anti-DENV IgM or IgG antibodies in patient serum, is the most extensively used approach for diagnosing dengue fever. Early detection and treatment of dengue fever help to lower morbidity and fatality rates associated with severe forms of the disease, as well as the danger of larger outbreaks. In 2025, the EIA/ELISA category dominated the immunoassay market, with a revenue share of 63.7%. Reduced test time, quantitative results, and the use of less antisera for analysis are some of the key advantages of this technology over Immunoelectrophoresis and immunodiffusion.
Furthermore, due to new product introductions, technological developments, and accuracy, RT-PCR testing is expected to rise at a significant rate. For example, in April 2022, Beroni Group Limited and Columbia University inked an exclusive license agreement under which Columbia University granted Beroni and its affiliates worldwide distribution rights to the patented CII-ArboViroPlex rRT-PCR assay.
Dengue Testing Market Regional Insights:
APAC is expected to account for significant market share during forecast period.
Because there are millions of instances of dengue infection each year, Asia Pacific is determined to be leading in the worldwide dengue testing market. Since 2009, the number of dengue cases in India has increased gradually, and the total number of deaths in 2025 was the most in the prior decade. Dengue fever is most prevalent in Southeast Asia, and the disease is on the rise. As a result of the rising frequency of infectious diseases, especially dengue fever, in India, Pakistan, and Sri Lanka, the market for dengue testing in the Asia Pacific is rapidly growing. There were 3.1 million instances in the American region alone, with over 25,000 of them categorized as severe. Despite the frightening number of infections, dengue-related mortality was down from the previous year.
The report also helps in understanding Global Dengue Testing Market dynamics, structure by analyzing the market segments and project the Global Dengue Testing Market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Global Market make the report investor’s guide.
Dengue Testing Market Recent Industry Developments
| Date | Company / Organization | Development | Impact |
|---|---|---|---|
| 29 October 2025 | F. Hoffmann-La Roche Ltd | Roche announced that it received the CE mark for its Elecsys Dengue Ag test, an automated, high-throughput immunoassay designed for its cobas e analyzers. | This clearance enables laboratories to achieve faster, automated testing workflows with a 18-minute turnaround time, drastically scaling diagnostic capacity during major seasonal outbreaks. |
| 15 January 2025 | VisGene Ltd | VisGene received full regulatory approval from the Thailand Food and Drug Administration and launched its VisCheck Dengue NS1 Rapid Antigen Serotyping Test. | The rollout introduces the world's first rapid point-of-care tool capable of simultaneously identifying all four dengue serotypes and predicting severe disease risk within 15 minutes. |
| 24 February 2025 | Brazil Ministry of Health | The Ministry announced a massive national procurement initiative to distribute 6.5 million dengue rapid diagnostic tests across the Unified Health System (SUS). | This marks the country’s first comprehensive, systematic deployment of combination diagnostics at the grassroots level to optimize early clinical triage and outbreak management. |
| 18 April 2025 | World Health Organization (WHO) | The WHO published updated interim global guidance on Laboratory Testing for Dengue Virus to standardize diagnostics amid escalating worldwide emergencies. | The directive strictly advocates for multiplex molecular assays and combination NS1+IgM rapid test usage, accelerating regulatory and procurement alignment for diagnostic manufacturers. |
| 26 August 2025 | U.S. Centers for Disease Control (CDC) | The CDC issued fresh Clinical Testing Guidance for Dengue targeting healthcare providers in response to expanding regional vector environments. | The policy tightens laboratory requirements by enforcing dual testing algorithms (NAAT alongside IgM or NS1 tests), altering commercial utilization trends in non-endemic clinical labs. |
Dengue Testing Market Scope: Inquire before buying
| Dengue Testing Market | |||
|---|---|---|---|
| Report Coverage | Details | ||
| Base Year: | 2025 | Forecast Period: | 2026-2034 |
| Historical Data: | 2020 to 2025 | Market Size in 2025: | USD 739.39 Mn. |
| Forecast Period 2026 to 2034 CAGR: | 5.5% | Market Size in 2034: | USD 1197.14 Mn. |
| Segments Covered: | by Test Type | ELISA-based Tests RT-PCR based Tests Dengue IgG/IgM Rapid Test Other Tests |
|
| by End-Users | Hospitals Diagnostic Centers Others |
||
Dengue Testing Market, by Region
North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria, Turkey, Russia and Rest of Europe)
Asia Pacific (China, India, Japan, South Korea, Australia, ASEAN and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina, Columbia and Rest of South America)
Dengue Testing Market, Key Players are
1. Molecular Diagnostics & PCR-Based Dengue Testing Companies
These companies develop molecular diagnostic assays that detect dengue viral genetic material with high accuracy during the early stages of infection.
North America
1. Thermo Fisher Scientific Inc. – United States
2. Bio-Rad Laboratories, Inc. – United States
Europe
1. F. Hoffmann-La Roche Ltd. – Switzerland
2. QIAGEN N.V. – Netherlands
Asia Pacific
1. Seegene Inc. – South Korea
2. Sansure Biotech Inc. – China
2. Rapid Diagnostic Test (RDT) Manufacturers
These companies develop rapid dengue tests that provide results within minutes using blood samples in hospitals, clinics, and point-of-care settings.
North America
1. Abbott Laboratories – United States
Europe
1. bioMérieux SA – France
Asia Pacific
1. SD Biosensor, Inc. – South Korea
2. J. Mitra & Co. Pvt. Ltd. – India
3. CTK Biotech, Inc. – Taiwan
3. Immunoassay & ELISA-Based Dengue Testing Companies
These companies provide ELISA and immunoassay platforms used to detect dengue antigens and antibodies.
North America
1. Abbott Laboratories – United States
2. Danaher Corporation – United States
Europe
1. bioMérieux SA – France
2. Siemens Healthineers AG – Germany
Asia Pacific
1. Sysmex Corporation – Japan
4. Clinical Diagnostics & Infectious Disease Testing Companies
These companies offer broad infectious disease testing portfolios that include dengue diagnostic solutions.
North America
1. Abbott Laboratories – United States
2. Danaher Corporation – United States
Europe
1. F. Hoffmann-La Roche Ltd. – Switzerland
2. bioMérieux SA – France
Asia Pacific
1. Sysmex Corporation – Japan
2. Seegene Inc. – South Korea
5. Point-of-Care & Emerging Dengue Diagnostics Developers
These companies focus on portable, decentralized, and next-generation dengue testing technologies.
North America
1. OraSure Technologies, Inc. – United States
Europe
1. EKF Diagnostics Holdings plc – United Kingdom
Asia Pacific
1. Molbio Diagnostics Pvt. Ltd. – India
2. SD Biosensor, Inc. – South Korea
Frequently Asked Questions:
1. Which region has the largest share in Global Dengue Testing Market?
Ans: Asia Pacific region held the highest share in 2025.
2. What is the growth rate of Global Dengue Testing Market?
Ans: The Global Dengue Testing Market is growing at a CAGR of 5.5% during forecasting period 2026-2034.
3. What is scope of the Global Dengue Testing market report?
Ans: Global Dengue Testing Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.
4. Who are the key players in Global Dengue Testing market?
Ans: The important key players in the Global Dengue Testing Market are – Thermo Fisher Scientific Inc., Roche Molecular Systems Inc., Abbott Laboratories, Abnova Corporation, InBios International, Inc., NovaTec Immundiagnostica GmbH, Euroimmun AG (Sub. PerkinElmer), Quest Diagnostics, Certest Biotec S.L., OriGene Technologies, Arkray Inc., Ceres Nanosciences Inc., Corgenix Medical Corp, FK-Biotecnologia SA, QuantuMDx Group Ltd., Sansure Biotech Inc., and Quidel Corp
5. What is the study period of this market?
Ans: The Global Dengue Testing Market is studied from 2025 to 2034.